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OBJECTIVES This study, performed in a murine model of encephalomyocarditis virus myocarditis, used a
new Millar 1.4F conductance-micromanometer system for the in vivo determination of the
left ventricular (LV) pressure-volume relationship (PVR).
BACKGROUND Viral myocarditis is an important cause of congestive heart failure and may lead to dilated
cardiomyopathy. However, the hemodynamic changes associated with its acute phase have
not been analyzed in detail.
METHODS Four-week-old DBA/2 mice were inoculated with EMCV (day 0). Serial hemodynamic
measurements, compared with uninfected control mice were made on days 0, 1, 3, 4, 5, 7, 9,
12, and 14.
RESULTS On day 1, the hearts of infected mice manifested enhanced contractile function, decreased LV
compliance, and abnormal diastolic function with increased LV end-diastolic pressure (EDP).
Mean stroke index, ejection fraction (EF), and cardiac index (CI) were significantly higher
than in uninfected control mice (p 0.05). Contractile function decreased from days 4 to 14.
On day 7, when hemodynamic abnormalities consistent with heart failure culminated,
end-diastolic volume (EDV), EDP, and EDPVR were significantly higher, and CI, EF,
end-systolic pressure (ESP), and ESPVR significantly lower in the infected than in control
mice. Heart rate remained comparable in both groups. Although heart failure receded
between day 9 and day 14, ESPVR, ESP, and EF remained significantly depressed up to day
14, and EDV and EDP remained significantly higher.
CONCLUSIONS These hemodynamic data provide new insights into the pathophysiology of acute viral
myocarditis and may be useful in the development of therapeutic interventions. (J Am Coll
Cardiol 2002;40:1506–14) © 2002 by the American College of Cardiology Foundation
Viral myocarditis is an important cause of congestive heart
failure (1). In its acute phase, it is associated with systolic
dysfunction, myocardial necrosis, and inflammatory cellular
infiltration. A clearer understanding of the disease’s patho-
physiology would help in the choice of appropriate treat-
ment. We have described a murine model of viral myocar-
ditis caused by the encephalomyocarditis virus (EMCV)
infection (1,2). Pathologic studies performed during the
acute phase in this model have shown the onset of visible
myocardial changes three days after virus inoculation. Focal
myocytolysis appeared on day 3, and necrotic myocardial
foci with infiltration of small mononuclear cells and inter-
stitial edema were present on day 5. Expansion of myocar-
dial necrosis was visible after day 7, becoming extensive
between day 10 and day 14. Dilation of the left ventricle
(LV) was prominent by day 8, increasing further between 10
and day 14, a stage when pleural effusion, pulmonary
congestion, and ascites developed (1). Pathological studies
were consistent with death from congestive heart failure,
although the hemodynamic characteristics of this and other
murine models of viral myocarditis have not been analyzed
in detail. This study applied the new conductance-
micromanometer system described by Georgakopoulos et al.
(3–6) to measure the LV pressure-volume relationships in
the acute phase of myocarditis in our in vivo model.
METHODS
Conductance catheter system design. We used the Millar
1.4F catheter (SPR-719, Millar Instruments, Houston,
Texas) composed of four conductance electrodes and a
micromanometer. The distance between the conductance
sensor electrodes is 4.5 mm (3). The conductance system
and the pressure transducer controller (Integral 3 [VPR-
1002], Unique Medical Co., Tokyo, Japan) were set at a
frequency of 20 kHz, the full-scale current selected at 20
A, and the pressure transducer at 5 V/V/100 mm Hg (7).
The pressure-volume loops and intracardiac electrocardio-
gram were monitored online, and the conductance, pressure,
and intracardiac electrocardiographic signals were digitized
at 2 kHz, stored on disk, and analyzed with Integral 3
software (Unique Medical Co., Tokyo, Japan) (7).
Surgical procedure. Mice were anesthetized with a mix-
ture of ketamine, 100 mg/kg, and xylazine, 5 mg/kg,
intraperitoneally; additional smaller doses were given occa-
sionally, as needed. The animals were placed in the supine
position under a dissecting microscope (model MZ75: Leica
Microsystems Wetzlar GmbH, Wetzlar, Germany), and a
vertical midline cervical incision was made to expose the
trachea by microsurgical techniques. After endotracheal
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intubation, the cannula was connected to a volume cycled
rodent ventilator (Shinano Co., Tokyo, Japan) with supple-
mental oxygen, a tidal volume of 7 l/g, and a respiratory
rate of 140/min. The right carotid artery and external jugular
vein were exposed via the same midline incision. To allow the
use of a physiologic closed-chest preparation (8), a 1.4F
SPR-719 Millar catheter was advanced via the right carotid
artery into the ascending aorta for measurements of aortic
pressure, then inserted into the LV. Left ventricular pressure-
volume relations were measured by transiently compressing the
inferior vena cava. The data were recorded as a series of
pressure-volume loops (about 20 loops). Parallel volume (Vp)
of each mouse was calibrated by the injection of 10 l of
hypertonic saline into the external jugular vein (9).
Measurements of right atrial (RA) pressure. A modified
0.014-in. Pressure Wire Sensor (Radi Medical System AB,
Uppsala, Sweden) was used for right atrial (RA) pressure
measurements (10). The pressure wire was inserted through
the external jugular vein into the RA and connected to the
Pressure Wire Interface (Radi Medical System AB, Upp-
sala, Sweden). The pressure tracings and surface electrocar-
diogram were monitored online (Biomedical Research Sys-
tem [LEG-1000], Nihon Koden Co., Tokyo, Japan). The
RA pressure was measured, and the pressure waveforms and
electrocardiogram were digitized at 2 kHz, stored to disk,
and analyzed with commercially available software (Nihon
Koden Co., Tokyo, Japan).
Volume calibration of the conductance catheter. The
volume calibration of this conductance system was per-
formed as described by Yang et al. (9). Briefly, seven
cylindrical holes in a block 1-cm deep and with known
diameters ranging from 1.4 to 5 mm were filled with fresh
heparinized whole murine blood. An interelectrode distance
of 4.5 mm was used to calculate the absolute volume in each
cylinder. In this calibration the linear volume-conductance
regression of the absolute volume in each cylinder versus the
raw signals acquired by the conductance catheter was used as
the volume calibration formula (Fig. 1) (5).
Analysis of the signals. All pressure-volume loop data
were analyzed with the Integral 3 software (Unique Medical
Co., Tokyo, Japan). Indexes of contractility and LV stiffness
were calculated, including end-systolic pressure (ESP) vol-
ume relationship (ESPVR), end-systolic volume (ESV)
elastance (Ees), stroke work (SW)-end-diastolic volume
relation (preload recruitable stroke work [PRSW]), slope of
maximum derivative of change in systolic pressure over time
(dP/dtmax)-EDV relation [(dP/dtmax)/EDV], end-diastolic
pressure volume relationship (EDPVR), and end-diastolic
volume elastance (Eed). The Ees and Eed were normalized by
100 mg of heart weight. The ventricular-to-vascular cou-
pling ratio was assessed by the arterial elastance (Ea)-to-Ees
ratio (Ea/Ees). The time constant of isovolumic relaxation
() was also calculated by linear regression of dP/dtmax
versus pressure from data between the minimum derivative
of change in diastolic pressure over time (dP/dtmin) and 5
mm Hg above EDP. Stroke volume (SV), cardiac output
(CO), and SW were normalized by body weight (stroke
volume index [SVI], cardiac index [CI], and SW index
[SWI], respectively). The systemic vascular resistance index
(SVRI) was calculated by the following equation: SVRI 
[mean aortic pressure (AOmean)  mean RA pressure
(RAmean)]/CI.
Experimental infection. A dose of 0.1 ml of the M variant
of EMCV diluted in Eagle’s modified essential medium
(Nissui Pharmaceutical Co., Tokyo, Japan) to a concentra-
tion of 1,000 plaque-forming U/ml was inoculated intra-
peritoneally in 32-day-old, 17 g, inbred male DBA/2 mice
(7). A dose of 0.1 ml of phosphate-buffered saline was
inoculated intraperitoneally to uninfected control mice. The
day of virus inoculation was defined as day 0.
Time course of hemodynamics in uninfected or infected
mice. On day 0, the uninfected group included 45 mice,
and the infected group included 200 mice. Serial hemody-
Abbreviations and Acronyms
AOmean  mean aortic pressure
dP/dtmax  maximum derivative of change in systolic
pressure over time
dP/dtmin  minimum derivative of change in diastolic
pressure over time
Ea  elastance of artery
EDPVR  end-diastolic pressure volume relationship
EMCV  encephalomyocarditis virus
ESPVR  end-systolic pressure volume relationship
NL Eed  normalized end-diastolic volume elastance
NL Ees  normalized end-systolic volume elastance
PRSW  preload recruitable stroke work
PVA  pressure-volume area  stroke work 
potential energy
RAmean  mean right atrial pressure
SVI  stroke volume index
SVRI  systemic vascular resistance index
SWI  stroke work index
SW/PVA  efficiency
Vp  parallel volume
Figure 1. Volume calibration of the conductance catheter. The absolute
volume in each cylinder was plotted against the raw signals of conductance
acquired by the conductance catheter. The regression formula, Y  1.466
 X  10.182 (R2  0.969; p  0.01) was used to calculate the raw and
parallel volumes.
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namic measurements were made in both groups on days 0,
1, 3, 4, 5, 7, 9, 12, and 14. The animals were randomly
selected to be catheterized at each time point. In the
infected group, when the measurements could not be made
for technical reasons, for instance when the animal died of
cardiogenic shock during the operation, or because of
arrhythmias, the data were excluded from analysis. None of
the uninfected mice died during an experiment. After the
successful collection of hemodynamic measurements, the
mice were sacrificed, the hearts were removed, and body and
heart were weighed.
Statistical analysis. Statistical comparisons were made by
analysis of variance with unpaired Student t test. The
standard volume lines were analyzed by simple linear regres-
sion. Values are expressed as mean  SE. A p value  0.05
was considered statistically significant.
RESULTS
Time course of hemodynamic function in uninfected
versus infected mice. Table 1 compares multiple indexes
of hemodynamic function in control versus infected mice on
day 1, day 7, and day 14. No difference was found between
the two groups at baseline. Heart rate remained stable in
both groups over the 14 days of observation.
Day 1. On day 1, at a stage when the hearts of infected
mice show no gross pathologic changes (1), contractility was
enhanced, diastolic function was abnormal, and EDP was
increased in the group of infected animals (Figs. 2A and
2B). The ESPVR in the infected mice had a markedly
steeper slope in comparison with controls (Fig. 2A). The
normalized Ees (NL Ees) of the infected mice was signifi-
cantly greater than that of the uninfected mice (p  0.05)
(Table 1, Fig. 3A). Consistent with the changes in ESPVR,
PRSW and (dP/dtmax)/EDV in infected mice were signif-
icantly greater than in controls (Table 1). The dP/dtmax and
dP/dtmin were significantly increased in the infected group
(Table 1, Fig. 2B), although these two parameters vary with
chamber volume, contractility, and heart rate. To normalize
for these factors, dP/dtmax/dP/dtmin (Fig. 3C), which is
independent of preload and afterload (4,5), was calculated
and was increased by approximately 72% in the infected
compared with the uninfected mice. In addition, , an index
of diastolic relaxation, was significantly longer in infected
than in uninfected mice (p  0.01, Table 1). Prolongation
of  and an increase in dP/dtmax/dP/dtmin are both indica-
tive of a delayed diastolic relaxation in the infected animals.
In addition to a delayed relaxation, chamber compliance
was decreased in the infected group. Figure 2A also shows
a markedly steeper slope of EDPVR in the infected group in
Table 1. Hemodynamics of EMCV-Infected and Uninfected Mice Based on Pressure-Volume Relations on Days 1, 7, and 14
Day 1 Day 7 Day 14
Uninfected Infected Uninfected Infected Uninfected Infected
BW (g) 17.8  0.2 17.4  0.3 20.9  0.1 10.6  0.2† 22.8  0.3 16.7  0.3†
HW (mg) 82.2  1.9 82.8  2.7 93.2  0.7 96.8  1.4* 98.2  1.2 99.0  1.6
HW/BW 4.6  0.1 4.8  0.1 4.5  0.1 9.2  0.1† 4.3  0.1 5.9  0.1†
HR (min1) 339  14 350  11 362  15 322  19 352  10 327  9
ESP (mm Hg) 73.0  1.4 91.4  3.4† 83.7  3.3 62.0  3.7† 93.2  3.2 80.7  1.5†
EDP (mm Hg) 1.10  0.12 3.48  0.21† 2.40  0.24 20.88  1.17† 1.60  0.24 15.46  0.39†
ESV (l) 9.22  0.17 6.92  0.86* 9.44  0.51 33.58  0.31† 11.00  1.09 36.38  0.56†
EDV (l) 24.42  0.92 23.45  0.78 27.06  0.59 38.92  0.38† 28.38  0.94 47.76  0.95†
SI (L/g) 0.85  0.05 0.95  0.01* 0.84  0.02 0.51  0.02† 0.76  0.01 0.68  0.07
EF (%) 62.1  1.0 70.8  2.6* 65.2  1.1 13.7  0.4† 61.6  2.5 23.7  2.2†
CI (l/min/g) 289  14 333  12* 305  12 164  16† 268  9 221  22
SWI (mm Hg  l/g) 62.1  3.7 86.3  3.9† 70.0  3.0 15.0  4.1† 70.6  2.0 32.7  6.2†
dP/dtmax (mm Hg/s) 7,772  231 10,175  312† 8,382  556 4,224  402† 9,742  317 8,256  163†
dP/dtmin (mm Hg/s) 5,137  209 3,942  315† 6,713  625 2,149  425† 8,498  341 5,764  680†
dP/dtmax/dP/dtmin 1.52  0.05 2.62  0.12† 1.26  0.05 2.15  0.25* 1.15  0.02 1.50  0.15*
 (ms) 10.40  0.30 14.32  0.73† 10.2  0.31 15.10  0.60† 10.25  0.48 13.40  1.03*
Ea (mm Hg/l) 4.87  0.29 5.53  0.24 5.73  0.25 11.73  0.98† 5.37  0.24 7.50  0.99
Ees (mm Hg/l) 9.09  0.28 13.34  1.54* 8.90  0.36 2.34  0.49† 8.56  0.50 2.97  0.48†
NL Ees (mm Hg/l  100 mg) 7.49  0.38 11.00  1.26* 8.28  0.28 2.26  0.47† 8.42  0.55 2.92  0.45†
Ea/Ees 0.53  0.03 0.43  0.04 0.54  0.05 5.76  0.95† 0.63  0.03 2.77  0.51†
NL Eed (mm Hg/l  100 mg) 0.12  0.01 0.46  0,06† 0.23  0.02 1.54  0.37† 0.32  0.03 0.36  0.07
PRSW (mm Hg) 77.0  2.2 85.7  2.4* 75.8  5.0 44.8  4.8† 74.0  3.3 56.9  4.4*
(dP/dtmax)/EDV (mm Hg/s/l) 413.4  18.9 838.0  108.4† 427.8  37.4 136.9  22.1† 424.4  18.5 202.7  22.0*
PVA (mm Hg  l) 1,401  82 1,822  65† 1,667  104 1,105  199† 2,123  57 1,789  225†
Efficiency (%) 78.5  8.5 82.2  12.8 78.6  1.4 13.4  2.9† 76.0  0.9 31.5  4.9†
AOmean (mm Hg) 58.6  1.4 78.4  3.4† 64.2  3.01 50.0  1.8† 72.2  2.1 61.8  0.6†
RAmean (mm Hg) 2.4  0.2 3.0  0.3 2.2  0.2 13.6  0.2† 2.2  0.2 8.8  0.2†
SVRI (mm Hg/ml  min  g) 196.0  7.3 227.6  11.3* 205.4  15.8 225.4  11.8 262.9  15.7 248.5  23.9
Values are means  SE. *p  0.05; †p  0.01 vs. uninfected control. n  5 in each.
For abbreviations, see the Abbreviation Box.
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Figure 2. Pressure-volume relations, left ventricular (LV) pressure, and slope of derivative of change in systolic pressure over time (dP/dt) curves in control
versus infected groups. A, C, E  pressure-volume relations. Light continuous curves are data from the uninfected control group. Continuous curves
are data from the infected group. Dotted lines indicate end-systolic and end-diastolic pressure volume relationships. B, D, F  LV pressure and dP/dt
curves. A, B  day 1; C, D  day 7; E, F  day 14.
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comparison with controls. Normalized Eed (NL Eed) in the
infected mice was significantly greater than in the uninfected
mice (p  0.05; Table 1, Fig. 3B). The EDP (Table 1,
Fig. 4A) was significantly increased in the infected mice
compared with controls (p  0.05), and EDV (Table 1, Fig.
4B) was decreased, though this difference was not statistically
significant. End-systolic pressure (Table 1, Fig. 4A) (p 
0.01), CI (Fig. 5A), ejection fraction (EF) (Fig. 5B), and SVI
(Table 1) were significantly higher in the infected group than
in the uninfected group (p  0.05). Finally SVRI, an index of
afterload, was significantly increased in the infected group (p
0.05, Table 1).
Day 3. On day 3, a stage at which small foci of myocardial
necrosis are found without evidence of cellular infiltration
(1), abnormal diastolic function persisted in the infected
mice, however, without findings of enhanced contractility
(Fig. 3A). The NL Ees, PRSW, and (dP/dtmax)/EDV were
comparable in both groups (Fig. 3A). , dP/dtmax/dP/dtmin,
dP/dtmin, and NL Eed were significantly increased in the
infected mice as well as EDP (p  0.05, Figs. 3B and 3C,
and 4A). End-systolic pressure, ESV, EDV, SVI, EF, CI,
dP/dtmax, RAmean, and SVRI were comparable in both
groups (Figs. 4A and 4B, and 5A and 5B).
Day 4. On day 4, contractility began to fall in the infected
mice (Fig. 3A). The NL Ees and (dP/dtmax)/EDV of the
infected mice were significantly lower than in the uninfected
mice (p  0.05). Delayed diastolic relaxation persisted, and
decreased chamber compliance further decreased. , dP/
dtmax/dP/dtmin, and dP/dtmin were significantly increased in
the infected mice (p  0.01, Fig. 3C), along with NL Eed,
EDP, and RAmean, compared with controls (p  0.01, Figs.
2B and 3A). Ejection fraction was significantly lower (p 
0.05, Fig. 5B), though SVI and CI were compensated by body
weight loss (Fig. 5A). End-systolic pressure, EDV, and dP/
dtmax were comparable in both groups (Figs. 4A and 4B).
Day 5. On day 5, decreased contractility and abnormal
diastolic function had progressed, the chambers began to
dilate, and cardiac output fell in the infected animals (Figs.
3A to 3C, 4B, and 5A). End-diastolic volume and ESV
were significantly greater in the infected than uninfected
mice (p  0.05 and p  0.01, respectively, Fig. 4B). The
NL Ees, PRSW, (dP/dtmax)/EDV, and dP/dtmax had fallen
significantly in the infected mice compared with the con-
trols (p  0.05, Fig. 3A). In contrast, , dP/dtmax/dP/dtmin,
dP/dtmin, NL Eed, EDP, and RAmean had increased signif-
icantly (Figs. 3B and 3C, and 4A). Finally, EF and CI were
decreased in the infected group (Figs. 5A and 5B), while
SVI and ESP were comparable in both groups (Fig. 4A).
Day 7. Changes consistent with heart failure culminated on
day 7. Decreased contractility, abnormal diastolic function,
chamber dilation, and low output had each progressed in the
infected mice (Figs. 2C and 2D, 4A and 4B, and 5A and
5B). The NL Ees, PRSW, (dP/dtmax)/EDV, dP/dtmax, EF,
ESP, CI, and SVI were significantly depressed in the
infected compared with the uninfected mice (Table 1).
Accordingly, , dP/dtmax/dP/dtmin, and dP/dtmin were sig-
nificantly, and EDV, ESV, NL Eed, EDP, and RAmean
markedly increased in the infected mice compared with the
controls (Table 1).
Figure 3. Evolution of contractility, myocardial relaxation, and chamber
compliance. Open circles  uninfected control group; solid circles 
infected group. dP/dtmax  slope of maximum derivative of change in
systolic pressure over time; dP/dtmin  minimum derivative of change in
diastolic pressure over time; NL Eed  normalized end-diastolic volume
elastance; NL Ees  normalized end-systolic volume elastance. *p  0.05;
**p  0.01 versus control. n  5 in each measurement.
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Days 9 to 14. Abnormal systolic and diastolic dysfunction
receded, though chamber dilation progressed between day 9
and day 14 (Figs. 2E and 2F, 4A and 4B, and 5A and 5B).
Though ESP, EDP, ESV, EF, dP/dtmax, dP/dtmin, dP/
dtmax/dP/dtmin, , NL Ees, PRSW, (dP/dtmax)/EDV, AOmean,
and RAmean each returned toward baseline between days 9 and
14, the differences between infected and uninfected groups on
day 14 remained statistically significant (Figs. 2E and 2F, 4A
and 4B, and 5B, Table 1). In contrast, SVI, CI, and NL Eed
returned toward baseline between days 9 and 14 to an extent
such that the differences between infected animals and controls
were no longer significant on day 14 (Fig. 5A, Table 1).
End-diastolic volume continued to increase past day 9 and, on
day 14, remained significantly greater in the infected than in
the uninfected mice (Fig. 4B).
The SVRI remained comparable in both groups from day
3 to day 14, while Ea rose significantly between day 4 and
day 12 in the infected group (Table 1).
Time course of efficiency of LV work. Efficiency of LV
work (SW/PVA) was depressed in the infected mice on
day 4, when the contractility began to decrease (Fig. 5C).
The fall in efficiency reached a nadir of 13.4  2.9% on day
7, in contrast with 78.6  1.4% in the uninfected group.
Past day 9, the efficiency in the infected mice recovered,
though remained significantly decreased on day 14 (p 
0.05). Concordant with these measurements of efficiency,
Ea/Ees increased past day 4 in the infected mice, reached its
peak on day 7, and recovered between day 9 and day 14
(Table 1). The SWI was decreased on day 5 when CI began
to decrease in the infected group, reached its peak on day 7,
and recovered between day 9 and day 14 (Table 1).
DISCUSSION
This study revealed that acute myocarditis induced by
EMCV was characterized by three phases of hemodynamic
evolution (Fig. 6):
1) A hyperdynamic phase was observed from day 1 to day 3.
In this phase, increases in contractility, cardiac output,
ESP, and vascular resistance were observed, probably
Figure 4. Evolution of left ventricular pressure and volume. (A) Pressure measurements. Circles  end-systolic pressure (ESP); squares  end-diastolic
pressure (EDP). (B) Volume measurements. Solid circles  end-diastolic volume (EDV); squares  end-systolic volume (ESV); open circles  control
group; solid circles  infected group. *p  0.05; **p  0.01 versus control. n  5 in each measurement.
1511JACC Vol. 40, No. 8, 2002 Nishio et al.
October 16, 2002:1506–14 Hemodynamics of Acute Viral Myocarditis
from activation of sympathetic activity, as has been
described in another type of viral infection (11). A
hyperdynamic state is often clinically observed in the
hyperacute phase of myocarditis, though has not been
specifically reported. It is noteworthy that diastolic
dysfunction was found concomitantly. Abnormal relax-
ation and increased chamber stiffness were present,
despite the known improvement in diastolic function
expected from catecholamines (12). This diastolic dys-
function may be caused by direct viral activity. Murine
cardiac troponin T is increased, and plaque assay shows
the presence of EMCV in the myocardial homogenate as
early as day 1 in this same model (13) (unpublished
data). Trivial injury to the plasma membrane and myo-
cardial structural proteins may be caused by the initial
viral attack on the myocytes, despite the absence of gross
pathologic abnormalities on day 1. Other immune me-
diators, including cytokines and proteins induced by
EMCV, may cause this abnormal diastolic function.
2) A depressive phase was observed between day 4 and day 7,
characterized by a progressive fall in contractility, lower
cardiac output, impaired myocardial relaxation, and de-
creased chamber compliance. Left ventricular dilation
was observed past day 5, while, on day 7, cardiogenic
shock and severe congestion were documented in these
experiments. Impaired contractility may be caused di-
rectly by myocyte injury and indirectly by nitric oxide
(NO) and cytokines, including tumor necrosis factor-
and interleukin-1. We have reported, in this model, the
expression of messenger RNA of inducible NO synthase
and of these cytokines, and the importance of these
mediators in its pathophysiology (13–17). The expres-
sion of these cytokines was significantly increased on day
3 and peaked on day 7 (13). Recent reports have
emphasized the importance of NO and cytokines in the
pathophysiology of congestive heart failure (13–21). The
well-described direct and indirect negative inotropic
effects of these immune-mediators are suspected to
explain the decrease in myocardial contractility observed
in this model (22–25). In addition, the progressive
diastolic dysfunction occurring during this phase may be
caused by myocytic injury, interstitial edema, and cellular
infiltrations. It has been reported that NO, in contrast
with its negative effects on systolic function, probably
improves diastolic function, and is one of the mediators
involved in compensatory mechanisms (26). However,
the tissue injury due to viral infection apparently pre-
vailed over the beneficial effects on diastolic function
conferred by NO.
3) A recovery phase was observed between day 9 and day 14,
during which contractility recovered slightly, and cham-
ber compliance improved markedly. The decrease in
contractility may have been caused by a fall in the
production of NO and cytokines, while the improvement
in chamber compliance may be explained by regressions
in interstitial edema and inflammatory cellular infiltra-
tions (1,2,13). Vascular resistance was not different
between the two groups, perhaps because of production
of NO and cytokines.
To the best of our knowledge, this is the first report of
hemodynamic measurements, particularly of pressure-
volume relationship and RA pressure, in an animal model of
Figure 5. Evolution of cardiac output, ejection fraction (EF), and left
ventricular work efficiency. Open circles uninfected control group; solid
circles  infected group. *p  0.05; **p  0.01 versus control. n  5 in
each measurement. CI  cardiac index.
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viral myocarditis. Our immunologic and molecular biologic
studies of viral myocarditis in an EMCV animal model,
which began in 1982, have provided important insights into
the mechanisms of the disease. In this new hemodynamic
study, distinct pathophysiologic abnormalities were identi-
fied, including a rapid and persistent fall, after an early
increase, in systolic function, although, on day 14 the
animals remained apparently vigorous. In contrast, diastolic
function decreased from day 1 to day 7, then improved
markedly to day 14. This improvement in diastolic function
compensated for systolic dysfunction, with remodeling and
dilation of the LV chamber. Therefore, the vitality of the
mice may have reflected the recovery from congestion by an
improvement of chamber compliance. These functional
anomalies and remodeling process are the results of direct
viral attack, immunological responses, including cytokine
production, and of endocrine activity probably vastly differ-
ent from the pathophysiology involved in ischemic or
valvular heart disease. A detailed description of the time
course of hemodynamic alterations and remodeling occur-
ring in the acute phase of viral myocarditis, as is presented
for the first time in this report, should be clinically helpful
to diagnose the disease, as well as plan its management.
Study limitations. We recognize some limitations in our
investigations. First, Vp was calibrated by the hypertonic
saline method. This method assumes that hemodynamics
are unchanged by the bolus of hypertonic saline (27).
However, volume loading and the hypertonicity of the
solution may both modify hemodynamics in this model.
There were no significant differences in EDP, ESP, dP/
dtmax, and dP/dtmin between measurements made immedi-
ately before the saline bolus and those made for the
determination of Vp in either the uninfected or the infected
group over the two weeks of study (Table 2). However, a
volumetric analysis was not performed. Ultrasonic crystal
measurements in mice have been reported, a method used in
open-chest conditions (28). While this method accurately
estimates LV volume, it could not be applied in this study,
because after day 5, the infected mice were intolerant of
open-chest surgery and any invasive cardiac intervention,
Figure 6. Pathophysiologic manifestations during three phases of acute encephalomyocarditis virus-induced myocarditis.
Table 2. Effect of Hypertonic Saline on Hemodynamics of EMCV-Infected and Uninfected Mice on Days 1, 7, and 14
Day 1 Day 7 Day 14
Uninfected Infected Uninfected Infected Uninfected Infected
ESP (mm Hg)
Baseline 72.9  2.3 91.6  3.3 83.5  3.1 62.2  3.7 93.0  2.9 80.9  1.6
Saline 74.1  2.5 93.3  4.0 85.8  4.0 63.9  3.8 95.3  3.3 81.5  2.5
EDP (mm Hg)
Baseline 1.22  0.18 3.41  0.29 2.51  0.30 20.98  1.22 1.70  0.23 15.31  0.40
Saline 1.42  0.33 3.63  0.45 2.79  0.33 21.30  1.64 1.91  0.30 15.82  0.53
dP/dtmax (mm Hg/s)
Baseline 7,799  349 10,389  355 8,405  518 4,315  392 9,873  423 8,249  233
Saline 7,983  299 10,491  390 8,697  412 4,429  518 9,997  586 8,306  187
dP/dtmin (mm Hg/s)
Baseline 5,141  259 3,892  419 6,724  683 2,146  456 8,316  419 5,739  651
Saline 5,209  343 4,016  396 6,992  571 2,248  429 8,470  585 5,813  639
Values are means  SE. There was no significance between data from immediately before saline bolus (baseline) and the peak of data acquisition for the determination of Vp
(saline) of both uninfected and infected groups. n  5 in each.
For abbreviations, see the Abbreviation Box.
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developing arrhythmias or sudden death. Likewise, echo-
cardiography could not be used because of the heavy
pericardial calcifications present in this model (1) and the
pronounced artifacts present in the small LV chambers of
uninfected, five-week-old mice. Magnetic resonance imag-
ing was not applicable because of its magnetic effects on the
experimental instrumentation. Finally, though unlikely, if
LV volume was modified by the saline bolus, EDV and
ESV would have been underestimated (27). Second, nor-
malization of the elastance by heart weight may or may not
be optimal (29). Elastance can be influenced by chamber
size. A decrease in Ees may have been caused by a significant
increase in heart weight in the infected group on days 5 and
7. Maximum systolic stiffness, which is derived from the
stress-strain relationship, is an index of LV contractility
independent of chamber size (28). Esposito et al. (28) have
described the in vivo stress-strain relationship in mice by the
ultrasonic crystal method (28). However, this elegant and
accurate method could not be applied in this model for
technical reasons described earlier. Despite the lesser accu-
racy of Ees normalized by heart weight, the difference in heart
weight between the two groups was small compared with that
of Ees on days 5 and 7. Furthermore, there was no significant
difference in heart weight between the two groups after day 9.
Therefore, we believe that the significant decrease in NL Ees in
the infected group after day 4 truly reflected a depression of
myocardial contractility in this study.
In conclusion, these hemodynamic observations made
during the first 14 days of murine EMCV-induced myo-
carditis provide new insights into the pathophysiology of the
acute phases of the disease, and may be useful in the
development of therapeutic interventions.
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